Dr. Nana Jin | Hearing loss | Best Researcher Award

Posted on by Pencis

Dr. Nana Jin | Hearing loss | Best Researcher Award

Institute for Translational Neuroscience of Affiliated Hospital 2 of Nantong University | China

Author Profile

Scopus

Orcid ID

🧠 NANA JIN: PIONEER IN TRANSLATIONAL NEUROSCIENCE

🎓 EARLY ACADEMIC PURSUITS

Nana Jin was born on March 21, 1986, in Anyang, Henan, China. Her academic journey began with a strong foundation in the life sciences. She earned her Bachelor of Science from the Life Science College of Henan Normal University in 2007. Driven by a passion for neuroscience, she pursued a Master of Science at the Key Laboratory of Neuroregeneration of Nantong University, where she honed her research skills and built the groundwork for her future contributions. She later achieved her Ph.D. in Medicine from the Medical School of Nantong University in 2022, deepening her expertise in neurodegenerative diseases.

🧪 PROFESSIONAL ENDEAVORS

Nana Jin's professional career spans over a decade of dedication to neurological research. She began as a junior researcher (2010–2014) at the Key Laboratory of Neuroregeneration, where she contributed to vital studies on neuronal repair. She was promoted to Assistant Researcher in 2014 and continued her work there until 2023.

In 2023, she transitioned to the Institute for Translational Neuroscience at the Affiliated Hospital 2 of Nantong University, where she initially served as an Assistant Researcher. Later that year, she was elevated to the role of Associate Researcher, reflecting her growing impact and leadership in the field.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON HEARING LOSS

Nana Jin's research centers on neurodegeneration, particularly the molecular mechanisms underlying tau pathology in Alzheimer’s disease and related disorders. Her investigative focus includes:

  • The inhibition of tau propagation under cerebral hypoperfusion.

  • The interplay between GSK3β and PP2A methyltransferase.

  • The role of TDP-43 and its cross-pathological associations with tau.

  • Targeted monoclonal antibody therapies against tau protein.

Her research also extends to diabetes-related gene function and kinase regulation in neurodegenerative contexts.

🌍 IMPACT AND INFLUENCE

Dr. Jin has played critical roles in several national-level research projects, both as Principal Investigator and as a key participant. Her work contributes significantly to our understanding of Alzheimer’s disease, and she has been part of innovative strategies for early intervention and therapeutic targeting. Her team’s achievements have laid the groundwork for clinical applications aimed at halting or reversing pathological brain changes.

📊 ACADEMIC CITES AND PROJECT FUNDING

Nana Jin’s work has been supported by prestigious grants such as:

  • National Natural Science Foundation General and Youth Projects.

  • Jiangsu Provincial Natural Science Foundation.

  • High-Level Talent Introduction Project.

She has been awarded over 4 million RMB in competitive research funding, demonstrating both the trust of the scientific community and the value of her contributions. Her published findings are frequently cited in the neurodegeneration research field, contributing to the global body of knowledge.

🏆 AWARDS AND HONOURS

Nana Jin's scientific excellence has earned her multiple accolades:

  • 🥇 2018 Jiangsu Provincial Government Scholarship for Overseas Study

  • 🏅 2015 Natural Science Award (Second Prize) from the Ministry of Education for her work on tau protein metabolism

  • 👩‍🔬 2015 Outstanding Scientific Innovation Team recognition from Jiangsu Higher Education Institutions

These honors reflect her recognized role in advancing neuroscience both in China and internationally.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Jin is poised to continue her trailblazing work in translational neuroscience, particularly in the prevention and treatment of Alzheimer’s disease. With her strong academic background, extensive research experience, and continued support from key institutions, she is expected to contribute significantly to future breakthroughs in neurodegenerative disease therapy and molecular brain research.

📑NOTABLE PUBLICATIONS

"Genome-wide profiling and functional characterization of circular RNAs in neural development and injury: insights from a rat model research" 

  • Authors: J., Yang, Jian , N., Jin, Nana , S., Zhang, Shuqiang, Z., Cui, Zhiming , L., Xu, Lian
  • Journal: Cellular and Molecular Life Sciences
  • Year: 2025

"Integrative mRNA and miRNA Expression Profiles from Developing Zebrafish Head Highlight Brain-Preference Genes and Regulatory Networks " 

  • Authors: S., Zhang, Shuqiang , J., Yang, Jian , J., Xu, Jie , N., Jin, Nana , X., Li, Xiaoyu
  • Journal: Molecular Neurobiology
  • Year: 2025

"From microsphere synthesis to neural tissue regeneration: Unraveling the potentials and progress" 

  • Authors: Y., Liu, Yaqiong , Y., Shang, Yuqing , Z., Wang, Zhen , Y., Yang, Yumin , G., Li, Guicai

Dina Jiesisibieke | Reproductive Health | Best Researcher Award

Posted on by Pencis

Ms. Dina Jiesisibieke | Reproductive Health | Best Researcher Award

Peking University Third Hospital | China

Author Profile

Scopus

Google Scholar

📌 DINA JIESISIBIEKE, M.D. CANDIDATE

🏥 CLINICAL MEDICINE AT PEKING UNIVERSITY THIRD HOSPITAL Peking University

🎓 EARLY ACADEMIC PURSUITS

Dina Jiesisibieke embarked on her medical journey at Peking University Third Hospital, where she has been pursuing a Doctor of Medicine (M.D.) degree since 2019. With an impressive GPA of 3.7/4.0, she has consistently demonstrated academic excellence and dedication to the field of clinical medicine. Her early academic years were marked by outstanding achievements, securing multiple scholarships and honors for her exceptional performance.

🏆 PROFESSIONAL ENDEAVORS

Beyond her academic pursuits, Dina has actively engaged in research and international exchange programs. In 2023, she participated in an exchange program at Mahidol University, where she gained hands-on experience in plastic surgery. This international exposure has broadened her clinical expertise and provided her with a global perspective on medical practices.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON REPRODUCTIVE HEALTH

Dina's research primarily focuses on reproductive medicine, specifically evaluating reproductive outcomes of conventional in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). Her work was recognized at the prestigious American Society for Reproductive Medicine (ASRM) conference in 2023, where she submitted a research abstract detailing her cohort study on reproductive outcomes.

🌍 IMPACT AND INFLUENCE

Dina's contributions extend beyond academic excellence, as she actively participates in scholarly discourse and medical research. Her involvement in clinical studies and international exchange programs positions her as an emerging leader in the medical field. Through her dedication to medical research and clinical training, she continues to inspire and set a benchmark for aspiring medical professionals.

📚 ACADEMIC CITATIONS

Her research has been recognized at a high level, with a conference abstract submitted to the American Society for Reproductive Medicine. This recognition highlights her growing influence in reproductive medicine and her commitment to contributing valuable insights to the medical community.

🏅 SCHOLARSHIPS AND AWARDS

Dina has been the recipient of numerous prestigious scholarships and awards, recognizing her academic excellence and dedication:

  • Merit Student of Peking University
  • Peking University Southwest Associated University Guan Yanhui Medical Education Scholarship (2019-2021)
  • Model Student of Academic Records of Peking University (2020-2024)
  • Peking University Weicai Pharmaceutical Scholarship (2021-2022)

🌟 LEGACY AND FUTURE CONTRIBUTIONS

As an aspiring physician, Dina Jiesisibieke is committed to advancing the field of clinical medicine and reproductive health. Her contributions to research, combined with her strong academic foundation and clinical experience, set the stage for a promising career in medicine. With continued dedication, she is poised to make a lasting impact in the field of reproductive medicine and beyond.

📑NOTABLE PUBLICATIONS 

"Prevalence of eye and adnexal disorders among elderly inmates in Taiwan prisons" 

  • Authors: C., Tsai, Chingyao , Z.L., Jiesisibieke, Zhu Liduzi , P., Tao, Ping , C., Chien, Chingwen , T., Tung, Taohsin
  • Journal: BMC Public Health
  • Year: 2024

Junhua Wu | Tumor Gene Therapy | Excellence in Innovation

Posted on by Pencis

Prof Junhua Wu | Tumor Gene Therapy | Excellence in Innovation

Nanjing University | China

Author Profile

Scoups

Orcid ID

JUNHUA WU: PIONEERING RESEARCHER IN BIOMECHANICS AND ONCOLOGY 🔬

EARLY ACADEMIC PURSUITS 🎓

Junhua Wu embarked on his academic journey at Nanjing University (NJU), where he earned both his BSc in Life Sciences (1998–2002) and PhD in Life Sciences (2002–2007). His doctoral studies laid a strong foundation in molecular biology and biomechanics, equipping him with the expertise to make significant contributions to scientific research.

PROFESSIONAL ENDEAVORS 🏅

Following his graduation in June 2007, Junhua Wu remained at Nanjing University as a faculty member. His academic career has progressed steadily:

  • Lecturer (Since September 2007)
  • Associate Professor (Since December 2014)
  • Professor (Since December 2019)

He has received research funding from prestigious sources such as the National Natural Science Foundation of China, Key R&D Plan of Jiangsu Province, Natural Science Foundation of Jiangsu Province, and the Doctoral Program Fund of the Ministry of Education.

As an esteemed scholar, Professor Wu has published over 50 SCI papers in high-impact journals such as Nature Communications and holds 17 national invention patents. He has also contributed to academia through the compilation and translation of scientific monographs. His editorial roles include serving on the boards of Translational Oncology, Biocell, and Discovery Medicine.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR GENE THERAPY🔍

Professor Wu has made groundbreaking contributions in biomechanics, material science, and oncology. His research interests focus on protein hydrogels, tumorigenesis mechanisms, and novel cancer therapies.

1. Creation and Application of Hydrogels 💧

His work on protein hydrogels was a pioneering achievement in the field of biomechanics. He successfully demonstrated the ability to manipulate the mechanical properties of macromaterials by fine-tuning single protein molecules. His study, published in Nature Communications (2018), was a landmark contribution and has been cited 110 times.

His work was recognized in the 100th-anniversary special issue of international macromolecular science and was selected by the China Biomechanics Professional Committee as a key research advancement (2016–2018).

2. Mechanism of Tumorigenesis and Development 🧬

Professor Wu’s contributions to oncology include his exosome theory of sorafenib resistance in hepatocellular carcinoma, published in JECCR (2016). This study has been cited 113 times, influencing subsequent research on drug resistance in various cancers. His findings provided a new understanding of cancer cell communication and treatment resistance.

3. Innovative Cancer Therapies 💊

Professor Wu has developed novel strategies for cancer treatment, leading to over 20 invention patents and more than 30 high-impact SCI publications.

His research on mechanically stable peptide-graphene oxide hybrid hydrogels for drug delivery was highlighted as a Web of Science highly cited paper (Top 1% globally). This work demonstrated precise drug release mechanisms and was recognized for its potential to revolutionize targeted cancer therapy.

His “Trojan Horse” strategy for oncolytic virus delivery represents another major breakthrough. Published in JECCR (2019), this method involves using graphene nanoflakes to enhance viral delivery to tumors, significantly improving therapeutic outcomes.

IMPACT AND INFLUENCE 🌍

Professor Wu’s research has had a profound impact on multiple disciplines, including biomechanics, biomaterials, and oncology. His pioneering studies have inspired global researchers, with scholars from institutions such as the University of Wisconsin-Milwaukee drawing on his ideas for their work in Nature Communications, Science Advances, and PRL.

His cancer therapy innovations have been widely cited and applied by leading oncologists and material scientists. His findings have been positively reviewed and referenced in major scientific publications, solidifying his reputation as a thought leader in the field.

ACADEMIC CITATIONS 📑

Professor Wu’s work has received extensive recognition, accumulating hundreds of citations. Some notable statistics include:

  • 110+ citations for his 2018 Nature Communications paper on protein hydrogels.
  • 113+ citations for his 2016 JECCR paper on exosome-mediated drug resistance.
  • 122+ citations for his 2015 Nanoscale paper on peptide-graphene oxide hybrid hydrogels.

LEGACY AND FUTURE CONTRIBUTIONS 🚀

Professor Junhua Wu’s legacy is defined by his interdisciplinary approach, bridging biomechanics, biomaterials, and cancer therapy. His innovative methodologies continue to shape biomedical engineering and oncology research.

Moving forward, he aims to:

  • Expand the applications of protein hydrogels for regenerative medicine and tissue engineering.
  • Advance tumor microecology studies to develop next-generation immunotherapies.
  • Refine oncolytic virus-based cancer treatments, enhancing their efficacy and clinical applications.

CONCLUSION 🏆

Junhua Wu stands as a pioneering figure in his fields of expertise. His work has redefined our understanding of mechanobiology and cancer treatment, earning him a place among the most influential scientists in modern biomedical research. His dedication to innovation ensures that his impact will continue to resonate for years to come.

NOTABLE PUBLICATIONS 📑

"SENP3 inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy" 

  • Authors: P., Wang, Peng , J., Qiu, Jiannan , Y., Fang, Yuan , J., Wu, Junhua , C., Jiang,
  • Journal: Chunping Cell Death and Differentiation
  • Year: 2025

"Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy" 

  • Authors: K., Liu, Kua , L., Kong, Lingkai , H., Cui, Huawei , C., Jiang, Chunping , J., Wu, Junhua
  • Journal: Cell Reports Medicine
  • Year: 2024

"CuET overcomes regorafenib resistance by inhibiting epithelial-mesenchymal transition through suppression of the ERK pathway in hepatocellular carcinoma" 

  • Authors: D., Ma, Ding , S., Liu, Shuwen , K., Liu, Kua , J., Wu, Junhua , C., Jiang, Chunping
  • Journal: Translational Oncology
  • Year: 2024

"Toward Practical Applications of Engineered Living Materials with Advanced Fabrication Techniques" 

  • Authors: C., Lu, Chenjing , Y., Huang, Yaying , J., Cui, Jian , Y., Cao, Yi , S., Yin, Sheng
  • Journal: ACS Synthetic Biology
  • Year: 2024

"Structurally and mechanically tuned macroporous hydrogels for scalable mesenchymal stem cell-extracellular matrix spheroid production " 

  • Authors: S., Yin, Sheng , H., Wu, Haipeng , Y., Huang, Yaying , W., Wang, Wei , Y., Cao, Yi
  • Journal: Proceedings of the National Academy of Sciences of the United States of America
  • Year: 2024

Kang Yang | Metabolic Disorders | Best Researcher Award

Posted on by Pencis

Dr. Kang Yang | Metabolic Disorders | Best Researcher Award

Northern Jiangsu People's Hospital affiliated with Yangzhou University | China

Author Profile

Scopus

Orcid Id

EARLY ACADEMIC PURSUITS 🎓

Kang Yang embarked on his academic journey at Shandong First Medical University, where he pursued a Bachelor of Medicine (BM) in 2017 under the mentorship of Professor Jianhong Qi. His early interest in sports medicine and rehabilitation laid a strong foundation for his future contributions in the field.

Building on this, he further honed his expertise at Yangzhou University, obtaining a Master of Medicine (MM) in 2020 under the guidance of Professor Xianghe Chen. His postgraduate studies deepened his understanding of rehabilitation techniques, patient care, and innovative treatments in sports medicine.

PROFESSIONAL ENDEAVORS 💼

As a rehabilitation physician and therapist, Kang Yang is committed to enhancing the quality of life for patients recovering from injuries, surgeries, and physical impairments. His work integrates advanced rehabilitation methodologies with patient-centered approaches to ensure effective recovery and functional restoration.

Throughout his career, he has actively contributed to both clinical practice and academic research, focusing on rehabilitation strategies tailored for athletes and individuals with musculoskeletal disorders.

CONTRIBUTIONS AND RESEARCH FOCUS ON METABOLIC DISORDERS🔬

Kang Yang’s research primarily revolves around sports medicine and rehabilitation medicine. His investigations explore:

  • Innovative rehabilitation techniques for sports-related injuries.
  • Physiological and biomechanical adaptations in long-distance runners and athletes.
  • Post-injury recovery protocols aimed at optimizing healing and preventing re-injury.

His dedication to research has led to significant advancements in sports rehabilitation, with a particular focus on marathon runners and endurance athletes.

IMPACT AND INFLUENCE 🔍

Kang Yang's contributions extend beyond clinical settings. His work has influenced:

  • Rehabilitation strategies for sports professionals.
  • Medical education, through his involvement in teaching and mentoring young medical students.
  • Public awareness on the importance of injury prevention and rehabilitation in sports.

His clinical expertise and research have helped shape modern rehabilitation protocols, making a positive impact on both patient outcomes and medical practices.

ACADEMIC CITATIONS AND RECOGNITION 🏆

Kang Yang’s academic excellence has been recognized through multiple prestigious awards:

  • Special Prize (2018) & First Prize (2019) at the Jiangsu Sports Graduate Innovation Forum.
  • 2019 National Scholarship for Postgraduates (China).
  • First-class academic scholarship from Yangzhou University.

These accolades highlight his commitment to academic excellence, research innovation, and contributions to the medical community.

LEGACY AND FUTURE CONTRIBUTIONS🏰

Looking ahead, Kang Yang aims to:

  • Expand his research on sports rehabilitation and injury prevention.
  • Develop advanced therapeutic protocols for athletes and individuals recovering from physical trauma.
  • Collaborate with international experts to enhance rehabilitation medicine globally.
  • Continue mentoring students and young professionals in the field of rehabilitation sciences.

His unwavering passion and dedication position him as a future leader in the evolving landscape of sports medicine and rehabilitation.

BEYOND MEDICINE: PERSONAL INTERESTS 📚

Outside of his professional life, Kang Yang enjoys:

  • Long-distance running and marathons, reflecting his deep understanding of sports medicine from both a theoretical and practical perspective.
  • Reading, staying updated with the latest medical advancements and broadening his intellectual horizons.

NOTABLE PUBLICATIONS📑

"Exercise alleviates renal interstitial fibrosis by ameliorating the Sirt1-mediated TGF-β1/Smad3 pathway in T2DM mice" 

  • Authors: X., Chen, Xianghe , X., Zeng, Xinyu , X., Qiu, Xiao , X., Zhou, Xiangxiang , K., Yang, Kang
  • Journal: Endocrine Connections
  • Year: 2024

Sara Salvador | Pharmacogenomics and Personalized Medicine | Best Researcher Award

Posted on by Pencis

Dr. Sara Salvador | Pharmacogenomics and Personalized Medicine | Best Researcher Award

Gregorio Maranon University Hospital | Spain

Author Profile

Scopus

Google Scholar

EARLY ACADEMIC PURSUITS

Since 2017, I have been dedicated to advancing the field of pharmacogenetics, beginning as a research assistant and progressing through to postdoctoral researcher at the Pharmacogenetics Laboratory of the Gregorio Marañón General University Hospital. My journey started with foundational research roles and evolved into leadership positions within various pharmacogenomic studies.

PROFESSIONAL ENDEAVORS

Starting as a research assistant, I gradually transitioned to roles as a predoctoral and postdoctoral researcher, accumulating invaluable experience and expertise in pharmacogenetics. My work has been primarily focused on pharmacogenomic studies in diverse medical areas such as colorectal cancer, multiple sclerosis, psychiatry, and intestinal inflammatory diseases.

CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACOGENMICS AND PERSONALIZED MEDICINE

Throughout my career, I have actively contributed to 21 publications in pharmacogenomics, with a particular emphasis on colorectal cancer, multiple sclerosis, psychiatry, and intestinal inflammatory diseases. Of these publications, I served as the first author for 14, showcasing my significant contributions to the field. Notably, my doctoral thesis in 2020 centered on intestinal inflammatory disease, underscoring my commitment to advancing knowledge in this area.

IMPACT AND INFLUENCE

My contributions have not gone unnoticed, as evidenced by receiving the AEFA (Spanish Clinical Laboratory Association) award for quality and innovation in 2019. Additionally, my research has been recognized through presentations at 20 national and international conferences, including 5 oral communications. I have been honored with the best oral communication award at three conferences, highlighting the impact of my work.

ACADEMIC CITES

My research has contributed to the academic discourse, with citations in various publications, further validating the significance and influence of my work in pharmacogenetics awards and related fields.

LEGACY AND FUTURE CONTRIBUTIONS

As an active member of the Spanish Society of Pharmacogenetics awards and the Spanish Association of Human Genetics, I continue to contribute to the advancement and dissemination of knowledge in these critical areas of public health. My ongoing commitment to research and collaboration ensures that my contributions will continue to shape the future of pharmacogenetics.

NOTABLE PUBLICATIONS

Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children 2023(3)

Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease 2023(7)

Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort 2023(7)

Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain 2022(5)

Pharmacogenetics to avoid adverse reactions in cardiology: Ready for implementation? 2021(4)